Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHO0136


Molecular Fingerprinting of Lung Cancer (SPORE)

Principal Investigator(s)

Pierre Massion


  • Protocol No. VICCTHO0136
  • Open Date: 05/01/2001
  • Staging: N/A
  • Age Group: Adults
  • Scope: Local
  • Objective:
  • Disease Sites: Lung; Non Small Cell
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Veterans Administration; St. Thomas Health Services; BAPT-Baptist Hospital (MEMPHIS); Vanderbilt University; Meharry Medical College
  • National Clinical Trial ID: NCT00897117
  • Secondary Protocol No: VICCTHO0136


None Provided.


Ages Eligible for Study:18 Years to 120 Years
Genders Eligible for Study:All
Accepts Healthy Volunteers:No


Inclusion criteria
• Diagnosis of non-small cell lung cancer
• Clinical stage I and II disease
• Resectable disease and complete surgical resection planned
• Treated on companion studies at Vanderbilt University, the Veterans Administration hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network
• Tumor specimen samples must be available at resection
Exclusion criteria
• Chemotherapy before surgery
• Radiotherapy before surgery